Dr. Gandara on Patient Selection for Molecular Testing

Video

In Partnership With:

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

David R. Gandara, MD, Director, Thoracic Oncology Program, University of California, Davis Comprehensive Cancer Center, discusses factors that help determine which patients with lung cancer should be tested for molecular aberrations.

Gandara believes that the best approach for determining whom to test is still debatable. However, new guidelines from IASLC and CAP recommend that all patients with adenocarcinoma should be tested for molecular abnormalities.

For EGFR and ALK aberrations, it has been suggested that the most cost-effective approach involves testing only never-smokers who have adenocarcinomas. However, Gandara explains that many former or light smokers are testing positive. The increasing frequency of these reports confirms the recommendations within the guidelines to test all patients with adenocarcinoma.

Moreover, Gandara notes that some patients with squamous cell carcinoma are also exhibiting ample actionable abnormalities that warrant molecular testing.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD